ArticleCancer immunology, immunotherapy : CII2010

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Håkan Norell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.